FDA perspectives on potential microarray-based clinical diagnostics

The US Food and Drug Administration (FDA) encourages the development of new technologies such as microarrays which may improve and streamline assessments of safety and the effectiveness of medical products for the benefit of public health. The FDA anticipates that these new technologies may offer th...

Descripción completa

Detalles Bibliográficos
Autores principales: Težak, Živana, Ranamukhaarachchi, Daya, Russek-Cohen, Estelle, Gutman, Steven I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525154/
https://www.ncbi.nlm.nih.gov/pubmed/16460648
http://dx.doi.org/10.1186/1479-7364-2-4-236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525154/
https://www.ncbi.nlm.nih.gov/pubmed/16460648
http://dx.doi.org/10.1186/1479-7364-2-4-236

Ejemplares similares